Conscience VC

Humane Genomics is focused on engineering precision-designed oncolytic viral therapies to selectively target and eliminate cancer cells using RNA viruses.

Junction is an AI-powered platform that intelligently automates retail workflows, enhancing revenue growth through no-code solutions. It specializes in automating processes such as content generation, forecasting, and data-driven decision-making for marketing, merchandising, and supply chain management.

Next Gen Cell Engineering & Drug Discovery

Tinyhealth is a pioneering company that offers the first gut health test specifically designed for babies, providing accurate insights tailored to their unique microbiome needs. Unlike other tests that rely on adult reference ranges, Tinyhealth's testing utilizes advanced sequencing technology to deliver actionable reports and recommendations for families.

MoldCo offers telehealth care and specialized lab testing for individuals affected by mold exposure, providing a comprehensive Detox & Repair program to restore health.

Integrated Biosciences is engineering the future of aging medicine by advancing research at the intersection of synthetic biology, chemistry, and computation, focusing on drug discovery and development to combat age-related diseases.

Pre-seed lead investor for deeply technical AI, biotech, climatetech and infrastructure startups, offering female operator-led go-to-market expertise and structured fellowships to source technical-founder deal flow. Divergent Capital is run by two female operator-investors who combine deep-tech investing experience with hands-on go-to-market expertise, and they cultivate deal flow through structured fellowships targeting students and emerging investors in their technical-founder network.

Stealthy investor across frontier sectors (space, biotech, AI) making sub-$500K average checks into technically complex startups with exceptional defensibility and operational guidance from GP Rob Ness's 2% Rule.

Bioscience investor translating grant-funded research into venture-scale companies, with a pipeline centered on engineering biology using robotic cloud labs and computational design for human health and planetary sustainability. The firm grew directly out of a philanthropic grants program at the Thiel Foundation that funded highly speculative science before spinning into a traditional venture fund.

Invests from napkin-stage through IPO using an evergreen own-capital model for patient, flexible long-term support; active early-stage investor (~180 deals) focused on deep bio and frontier software/crypto.

Early institutional backer that sources tech from academia and government labs, partnering with scientist- and engineer-led teams to deeply interrogate science, dual-use/defense opportunities, and amplify through an in-house media platform. Explicitly aims to "turn science fiction into science fact" by backing companies at the intersection of the new and the not-yet-imagined, built around scientists, engineers, and polymaths rather than traditional finance backgrounds who can deeply interrogate emerging science and complex tech. The firm systematically mines academia and government labs for "technological gems" and has become one of the earliest institutional backers of dual-use and defense technology.